Grace Therapeutics Inc

Grace Therapeutics Inc specializes in the creation and commercialization of pharmaceutical products primarily targeting uncommon and neglected diseases with operations centered in Canada The companys most advanced experimental treatment is GTX104 an intravenous infusion designed to address subarachnoid hemorrhage Its development pipeline further includes GTX102 an oral mucosal betamethasone spray intended for the management of ataxiatelangiectasia and GTX101 a topical bioadhesive filmforming bupivacaine spray for postherpetic neuralgia Established in 2002 the enterprise previously operated under the name Acasti Pharma Inc before officially adopting Grace Therapeutics Inc in October 2024 The companys main offices are located in Princeton New Jersey